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Abstract
OBJECTIVE: To investigate the relationship in ma-
lignant-neoplasm patients of hypercoagulability
between syndromes differentiated with the theory
of abnormal hilit in traditional Uyghur medicine
(TUM).
METHODS: A total of 248 patients with malignant
tumors were enrolled. Based on the theory of TUM
they were divided into two groups: abnormal Sav-
da and abnormal Non-Savda (including abnormal
Khan, abnormal Sepra and abnormal Belghem
types); fifty healthy volunteers were selected as
controls. Platelet (PLT), prothrombin time (PT), plas-
ma fibrinogen (FIB), thrombin time (TT), activated
partial thromboplastin time (aPTT) and D-Dimer
(D-D) were measured in both groups.
RESULTS: Compared with the control and abnor-
mal Non-Savda groups, in the abnormal Savda
group the PLT count increased (P<0.05), the PT was
lengthened (P<0.01), and the FIB significantly in-
creased (P<0.01). D-Ds in the three groups were sig-
nificantly different (P<0.05). No significant differ-
ence was found in TT and aPTT values (P>0.05).
CONCLUSION: Hypercoagulability existed in pa-
tients with malignant tumors in the different types
of TUM syndromes, especially in the abnormal Sav-
da group; this was characterized by increased
blood viscosity, platelet aggregation and thrombo-
sis. D-D appears to be a significant predictor for the
therapeutic effect of TUM in relation to malignant
tumor therapies.
© 2014 JTCM. All rights reserved.
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INTRODUCTION
Cancers cause significant morbidity and mortality and
are a major international public health problem.
Thrombosis is the second leading cause of death
among patients with malignant tumors. Different de-
grees of blood clotting exist in patients who are suffer-
ing from cancer. Hypercoagulability is a pre-thrombot-
ic state, which increases the risk of thrombosis. Throm-
bocytosis of malignant solid tumors may cause abnor-
mal coagulation, such as thrombosis and a tendency to
hemorrhage;1,2 it also plays an important role in disease
progression and metastasis. Platelets also participate in
the growth of primary and metastatic tumors, and an-
30
Chen Y et al. / Clinical Study
JTCM |www. journaltcm. com February 15, 2014 |Volume 34 | Issue 1 |
giogenesis. The secretion of vascular endothelial
growth factor (VEGF) from platelets is an early indica-
tion of the development of malignant tumors.3,4
Traditional Uyghur medicine (TUM) has been prac-
ticed for several millennia. Its theory is used for the pre-
vention and treatment of cancers. According to TUM
'hilit' (body fluid) theory, body fluid is assembly of
complex matter generated from a variety of nutrients,
the four essential bodily fluids are Kan (blood), Belgh-
en (phlegm), Sapra (yellow bile) and Savda (black bile).
These need to be kept in balance to keep the body
healthy; alteration of one or more of these fluids may
cause illness. The syndromes generally described in
TUM are divided into four main categories: abnormal
Kan, abnormal Belghen, abnormal Sapra, and abnor-
mal Savda syndrome. According to TUM, abnormal
Savda is a special syndrome of abnormal hilit in the
body, and not only increases tumorigenic probability,
but is also the main cause and common foundation of
tumors.5,6
In this study we investigated, from the viewpoint of hil-
it theory of TUM, the association of hypercoagulabili-
ty in cancer patients with the syndromes of abnormal
hilit, with the hope of finding evidence for guiding the
medical practice of TUM.
METHODS
Subjects
From January 2012 to December 2012, a total of 248
tumor patients (107 males, 141 females) with a defini-
tive pathological diagnosis were enrolled in the study at
the Fourth Affiliated Hospital of Xinjiang Medical Uni-
versity. The types of tumors are shown in Table 1.
TUM syndrome differentiation in accordance with
standard diagnoses,7 was carried out by TUM practitio-
ners. Based on the syndromes of TUM, the cancer pa-
tients were divided into two groups: abnormal Savda
and abnormal Non-Savda (including abnormal Khan,
abnormal Sepra, and abnormal Belghem). Fifty healthy
volunteers (19 males, 31 females) without confirmed
benign proliferative disorders which is correlated to tu-
mor who were selected from the check-up department
at the hospital, served as a control group. The study
protocol was approved by the Ethics Committee of
The Fourth Affiliated Hospital of Xinjiang Medical
University. All subjects gave written informed consent.
The trial registration number is ChiCTR-ocs-
12002275.
Measurement of platelets, prothrombin time, plasma
fibrinogen, thrombin time, activated partial
thromboplastin time, and D-Dimer
Platelet (PLT) counts, prothrombin time (PT), plasma
fibrinogen (FIB), thrombin time (TT), activated par-
tial thromboplastin time (aPTT) and D-Dimer (D-D)
were measured. A fasting venous blood sample (2 mL)
was collected from each participant between 0800 and
0900 h (before breakfast) using a blood collection tube
(provided by Shandong Aosaite Medical Instrument
Co. Ltd., Shandong, China). PLT counts were deter-
mined by SYSMEX XT-2000i (Japan SYSMEX (Mr
Sen business) Co. Ltd., Koba, Japan) over 2 h at room
temperature (about 22℃). A fasting venous blood sam-
ple (2 mL) was collected using a PT tube (provided by
Shandong Aosaite Medical Instrument Co. Ltd., Shan-
dong, China) from each participant between 0800 and
0900 h (before breakfast); PLT levels were determined
by AMAX200 (Germany) over 2 h at room tempera-
ture (about 22℃).
Statistical analysis
Data are shown as mean ± standard deviation (SD).
ANOVA and rank sum test were used to analyze the
difference between groups. Data were analyzed using
SAS JMP Statistical Discovery v9.0.2 (SAS institute
Inc., Cary, NC, USA) P<0.05 was used as the signifi-
cance level.
RESULTS
Compared with the control and abnormal Non-Savda
groups, in the abnormal Savda group the PLT count in-
creased (P<0.05), the PT was lengthened (P<0.01),
and the FIB significantly increased (P<0.01). No signif-
icant difference was found between the abnormal Non-
Cancer type
Lung cancer
Breast cancer
Esophageal cancer
Stomach cancer
Intestinal cancer
Other
Total
n
(abnormal Savda group)
54
29
13
24
25
20
165
n (abnormal Nonsavda group)
Abnormal Belghen
6
19
0
5
3
7
40
Abnormal Sapra
9
13
3
2
3
3
33
Abnormal Kan
4
2
1
1
1
1
10
Table 1 Observed cancers in the study participants
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Savda group and the control group (P>0.05) (Table 2).
Table 3 shows that no significant correlation was de-
tected in the serum levels of TT and APTT among the
three groups (P>0.05). Data relating to D-D were
skewed, and the results are presented as medians (up-
per and lower quartile range). The serum levels of D-D
increased significantly in the abnormal Savda group (P<
0.01) compared with the abnormal Non-Savda group
and control group (P<0.05). Further, a significant dif-
ference was present between the abnormal Non-Savda
group and control group (P<0.05).
DISCUSSION
This study shows that platelet levels in the abnormal
Savda group and abnormal Non-Savda group were sig-
nificantly higher than in the control group. Abnor-
mal Savda syndrome patients that have cancer may
possess a defect in the blood coagulation mechanism
(hypercoagulability state), which increases the risk of
disease progression, invasive metastases, and a poorer
prognosis.
Platelets, TT, aPTT and FIB can be used to evaluate
coagulation function. The PT was prolonged in the ab-
normal Savda group compared with the abnormal
Non-Savda group (including abnormal Khan, abnor-
mal Sepra and abnormal Belghem types (P<0.05). Our
study suggests that abnormal Savda patients with malig-
nant tumors may lack clotting factors. Fibrinogen is an
important coagulation factor in plasma and the central
protein in the coagulation system. It can induce plate-
let aggregation, and release stimulating factors and asso-
ciated antigens. The latter play a vital role in the regula-
tion of platelet adhesion to the walls of damaged ves-
sels. As a bridge between the activated platelets, it can
bind to platelet membrane glycoprotein receptors (GPⅡb/Ⅲa), link them, and promote platelet aggregation
and thrombosis. The present study demonstrates that
compared with the control and abnormal Non-Savda
group, the level of FIB significantly increased in the ab-
normal Savda group (P<0.05). This suggested that the
tumor patients with abnormal Savda syndrome had a
greater extent of hypercoagulability.
Currently, D-D can be used as one of the molecular
markers of hypercoagulability and hyperfibrinolysis,
the levels of which correlate with tumor load, staging,
and the number of metastases.8 D-D in tumor patients
can be used as a separate factor regarding blood clots.9
Our study shows that patients were at risk of thrombo-
sis if they had a malignant tumor belonging to the dif-
ferent types of abnormal TUM syndromes, especially
those with abnormal Savda. Hypercoagulability
changes were more obvious in the abnormal Savda
group. D-D is likely to be a significant predictor of
TUM therapy, for the treatment of patients with malig-
nant tumors.
In conclusion, hypercoagulability existed in patients
with malignant neoplasms. The degree of hypercoagu-
lability varied between the groups, depending on the
syndromes as differentiated with TUM. especially in
the abnormal Savda group; this was characterized by
increased blood viscosity, platelet aggregation and
thrombosis.
Table 2 Levels of PLT, PT and FIB in all groups ( xˉ ±s)
Group
Abnormal Savda group
Abnormal Nonsavda group
Control group
F
P value
n
165
83
50
-
-
PLT (×109/L)
218.15±6.53a
195.46±9.205b
189.06±11.86b
3.389
0.035
PT (s)
12.18±0.15c
11.53±0.21b
11.03±1.28b
7.728
0.001
FIB (g/L)
3.59±1.06c
3.14±0.82b
2.89±0.65b
13.651
<0.000
Notes: abnormal Savda group and abnormal Nonsavda group were cancer patients; control group were healthy volunteers. PLT: Platelet;
PT: prothrombin time; FIB: plasma fibrinogen. aP<0.05 compared with the control group; bP<0.05 compared with the abnormal Savda
group; cP<0.01 compared with the control group.
Group
Abnormal Savda group
Abnormal Unsavda group
Control group
F
P value
n
165
83
50
-
-
TT (s)
18.0±5.0
18.0±1.7
17.9±1.5
0.026
0.975
aPTT (s)
31.3±18.1
27.0±5.0
29.1±4.1
2.782
0.064
D-D (μg/L)
168116, 494a
12690, 179bc
8853.25, 146.25c
6.598
0.002
Notes: abnormal Savda group and abnormal Nonsavda group were cancer patients; control group were healthy volunteers. TT: thrombin
time; aPTT: activated partial thromboplastin time; D-D: D-Dimer. aP<0.01 compared with the control group; bP<0.05 compared with
the control group; cP<0.05 compared with the abnormal Savda group.
Table 3 Levels of TT, APTT and D-Dimer in all groups
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